Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.…
Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response
Enlivex (NASDAQ: ENLV) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 34 employees.
The shares were at 1.050 USD on 20 November 2026, down 99.6% over 52 weeks. Its 52-week range is 1.000 USD to 434.40 USD: the price is 99.8% below the high and 5.0% above the low.
Its market capitalisation is 2.01M USD.
Enlivex reports return on equity of 63.9% and an operating margin of 0.0%.
Its debt exceeds its cash by 12.03M USD, a debt-to-equity ratio of 0.00. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.